ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för edoxaban. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

24 träffar

Bibliografisk träff 2015-07-02

An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.

Mendell J, Johnson L, Chen S.

J Clin Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1002/jcph.550

Bibliografisk träff 2015-06-30

Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study.

Jönsson S, Simonsson US, Miller R, Karlsson MO.

J Clin Pharmacol · controlled clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1002/jcph.541

Bibliografisk träff 2015-06-26

Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule.

Parasrampuria DA, Kanamaru T, Connor A, Wilding I, Ogata K, Shimoto Y, Kunitada S.

J Clin Pharmacol · research support, non-u.s. gov't; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1002/jcph.540

Bibliografisk träff 2015-05-28

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation.

Acharya T, Deedwania P.

Core Evid · review-article; review; journal article · DOI 10.2147/ce.s61441

Bibliografisk träff 2015-05-13

Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial.

Steffel J, Giugliano RP, Braunwald E, Murphy SA, Atar D, Heidbuchel H, Camm AJ, Antman EM, Ruff CT.

Eur Heart J · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1093/eurheartj/ehv201

Bibliografisk träff 2015-04-28

Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment.

Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M.

Circ J · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1253/circj.cj-14-0942

Bibliografisk träff 2015-04-08

Edoxaban, a Novel Oral Factor Xa Inhibitor.

Minor C, Tellor KB, Armbruster AL.

Ann Pharmacother · review; journal article · DOI 10.1177/1060028015579426

Bibliografisk träff 2015-04-01

Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.

Cuker A, Husseinzadeh H.

J Thromb Thrombolysis · research-article; systematic review; journal article; research support, n.i.h., extramural · DOI 10.1007/s11239-015-1185-7

Bibliografisk träff 2015-04-01

A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.

Tangelder MJ, Nwachuku CE, Jaff M, Baumgartner I, Duggal A, Adams G, Ansel G, Grosso M, Mercuri M, Shi M, Minar E, Moll FL.

J Endovasc Ther · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1177/1526602815574687

Bibliografisk träff 2015-03-11

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, Murphy SA, Lee J, Mercuri MF, Giugliano RP, Antman EM, Braunwald E, Sabatine MS.

Lancet · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(14)61994-2

Bibliografisk träff 2015-03-11

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM.

Lancet · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(14)61943-7

Bibliografisk träff 2015-03-09

Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists.

Honda Y, Morishima Y.

Thromb Res · journal article · DOI 10.1016/j.thromres.2015.03.001

Bibliografisk träff 2015-03-01

Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban.

Noguchi K, Morishima Y, Takahashi S, Ishihara H, Shibano T, Murata M.

Blood Coagul Fibrinolysis · research support, non-u.s. gov't; journal article · DOI 10.1097/mbc.0000000000000147

Bibliografisk träff 2015-02-21

A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.

Lip GY, Merino J, Ezekowitz M, Ellenbogen K, Zamoryakhin D, Lanz H, Jin J, Al-Saadi N, Mercuri M, Goette A.

Am Heart J · comparative study; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.ahj.2015.02.009

Bibliografisk träff 2015-02-16

Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.

O'Donoghue ML, Ruff CT, Giugliano RP, Murphy SA, Grip LT, Mercuri MF, Rutman H, Shi M, Kania G, Cermak O, Braunwald E, Antman EM.

Eur Heart J · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1093/eurheartj/ehv014

Bibliografisk träff 2015-02-07

Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials.

Loffredo L, Perri L, Violi F.

Dig Liver Dis · meta-analysis; journal article · DOI 10.1016/j.dld.2015.01.159

Bibliografisk träff 2015-02-01

Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.

Rognoni C, Marchetti M, Quaglini S, Liberato NL.

J Thromb Thrombolysis · comparative study; journal article · DOI 10.1007/s11239-014-1104-3

Bibliografisk träff 2015-02-01

Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage.

Herzog E, Kaspereit F, Krege W, Doerr B, Mueller-Cohrs J, Pragst I, Morishima Y, Dickneite G.

Anesthesiology · research support, non-u.s. gov't; journal article · DOI 10.1097/aln.0000000000000520

Bibliografisk träff 2015-02-01

Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.

Morishima Y, Kamisato C.

Am J Clin Pathol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1309/ajcpq2njd3pxftug

Bibliografisk träff 2015-01-30

A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery.

Fuji T, Fujita S, Kawai Y, Abe Y, Kimura T, Fukuzawa M, Abe K, Tachibana S.

Thromb J · research-article; journal article · DOI 10.1186/s12959-014-0034-9

Bibliografisk träff 2015-01-08

Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.

Parasrampuria DA, Marbury T, Matsushima N, Chen S, Wickremasingha PK, He L, Dishy V, Brown KS.

Thromb Haemost · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1160/th14-06-0547

Bibliografisk träff 2014-11-22

Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis.

Nielsen PB, Lane DA, Rasmussen LH, Lip GY, Larsen TB.

Clin Res Cardiol · meta-analysis; research support, non-u.s. gov't; systematic review; journal article · DOI 10.1007/s00392-014-0797-9

Bibliografisk träff 2014-11-17

Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.

Zahir H, Brown KS, Vandell AG, Desai M, Maa JF, Dishy V, Lomeli B, Feussner A, Feng W, He L, Grosso MA, Lanz HJ, Antman EM.

Circulation · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1161/circulationaha.114.013445

Bibliografisk träff 2014-10-14

Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach.

Verdecchia P, Angeli F, Bartolini C, De Filippo V, Aita A, Di Giacomo L, Poltronieri C, Lip GY, Reboldi G.

Expert Opin Drug Saf · meta-analysis; research support, non-u.s. gov't; journal article · DOI 10.1517/14740338.2014.971009